Capacity FVC

Related by string. * capa city . cap acity . CAPACITY . capacity : Operator Refinery Capacity Description . Capacity Expansion . refining capacity . Capacity Building . Capacity Utilization . High Capacity SDHC . Production Capacity . capacity utilization . Capacity Legal Footnote . Capacity . nameplate capacity . capacity #Q'# Motiva / fvc : FVC Valley . FVC Fox . FVC crossover . FVC Meet . FVC * *

Related by context. Frequent words. (Click for all words.) 64 ACR# response 61 clinically meaningful improvement 61 IPSS 60 International Prostate Symptom 60 Expanded Disability Status 60 Montgomery Asberg Depression 60 Psoriasis Area 60 virologic response 59 annualized relapse 59 Alzheimer Disease Assessment 58 Response Evaluation Criteria 58 ADAS cog 58 prospectively defined 58 univariate 58 sensitivity specificity 57 HbA1C 57 Negative Syndrome 57 cytogenetic response 57 platelet reactivity 57 fasting insulin 56 Pharmacokinetic 56 fasting plasma glucose 56 Secondary endpoints 56 Main Outcome Measures 56 secondary efficacy endpoints 56 undetectable HCV RNA 56 HSCT 55 Atopic Dermatitis 55 OGTT 55 univariate analysis 55 Heart Failure Patients 55 multivariate analyzes 55 nonfatal myocardial infarction 55 biochemical recurrence 55 estimated glomerular filtration 55 microalbuminuria 55 Patient Outcomes 55 RECIST criteria 55 cardiac dysfunction 55 FEV1 55 serum testosterone 55 NLX P# 55 Currency Majors Technical 55 Depressive symptoms 55 glycosylated hemoglobin 54 Kaplan Meier 54 Unified Parkinson Disease 54 sustained virologic response 54 glomerular filtration rate 54 creatinine levels 54 lymphopenia 54 cystatin C 54 glycated hemoglobin 54 Postoperative 54 Natural Catastrophe Stress 54 plus methotrexate 54 virologic 54 plus dexamethasone 54 QTc prolongation 54 FOLFOX4 54 serum PSA 54 hemoglobin A1C 54 DAS# [002] 54 laboratory abnormalities 54 Prostate Cancer Risk 54 Prognostic 53 concomitant medications 53 Acute Coronary Syndromes 53 Health Assessment Questionnaire 53 TAXUS p value 53 mg BID 53 carotid stenosis 53 creatinine clearance 53 CK MB 53 Secondary endpoints included 53 hypokalemia 53 serum vitamin D 53 HbA 1c 53 CDAI 53 CI -#.# 53 secondary endpoint 53 Arch Intern Med 53 Thrombocytopenia 53 p = .# [002] 53 efficacy endpoint 53 virologic failure 53 serum uric acid 53 Thrombolysis 53 C Reactive Protein 53 Study Demonstrates 53 % CI #.#-#.# [003] 53 NHANES III 53 MADRS 53 confidence interval #.#-#.# 52 mucosal healing 52 seroprotection 52 hemoglobin concentration 52 Dyslipidemia 52 TAXUS Stent 52 Opns 52 APTIVUS

Back to home page